Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Ulrich Mey(Kantonsspital Graubünden), Ingo G.H. Schmidt‐Wolf(University Hospital Bonn), John Strehl(University of Bonn), Josef Birkmann(Paracelsus Medizinische Privatuniversität), Andreas Neubauer(RWTH Aachen University), Dimitri Flieger(Klinikum Aschaffenburg), Marcus Gorschlüter(University of Bonn), Christian Rabe(The University of Texas MD Anderson Cancer Center), Ulrich Kaiser(University of Applied Sciences Landshut), Axel Glasmacher(University Hospital Bonn), Cordula Bopp(University of Bonn), Corinna Hahn(University of Bonn), Martin Wilhelm(University of Würzburg), Manfred Hensel(Heidelberg University), Axel Florschütz(Städtisches Klinikum Dessau), Anthony D. Ho(Heidelberg University), Katjana Orlopp(University of Bonn)
Cited by 61
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Replicative Senescence of Mesenchymal Stem Cells: A Continuous and Organized Process
|PLoS ONE|2008|1.1k
Immunochemotherapy With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Significantly Improves Response and Time to Treatment Failure, But Not Long-Term Outcome in Patients With Previously Untreated Mantle Cell Lymphoma: Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG)
|Journal of Clinical Oncology|2005|573